Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
- Resource Type
- Article
- Source
- Lancet Respiratory Medicine; May2020, Vol. 8 Issue 5, p453-460, 8p
- Subject
IDIOPATHIC interstitial pneumonias INTERSTITIAL lung diseases DIAGNOSIS HYPERSENSITIVITY pneumonitis IDIOPATHIC pulmonary fibrosis SUBGROUP analysis (Experimental design) CARBON monoxide - Language
- ISSN
- 22132600